Jeff Evanson serves as Executive at Outlook Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Jeff Evanson has executed 9 insider transactions totaling $736.7K, demonstrating a bearish approach to their equity position. Their most recent transaction on Mar 7, 2024 involved purchasing 62,484 shares valued at $26.2K.
Jeff Evanson currently holds 808,459 shares of Outlook Therapeutics, Inc. (OTLK), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Jeff Evanson has been a net seller of OTLK stock. They have purchased $73.4K and sold $663.3K worth of shares.
Jeff Evanson's most recent insider trade was on Mar 7, 2024, when they purchased 62,484 shares at $0.42 per share.
Get notified when new Form 4 filings are submitted
| $1.11 |
| Discretionary |
| Jan 19, 2023 | OTLK | $126.0K | Sale | 103,255 | $1.22 | Discretionary |
| Jan 18, 2023 | OTLK | $42.2K | Sale | 33,738 | $1.25 | Discretionary |
| Jan 17, 2023 | OTLK | $35.6K | Sale | 27,162 | $1.31 | Discretionary |
| Dec 3, 2021 | OTLK | $47.2K | Purchase | 35,200 | $1.34 | Discretionary |
| Feb 23, 2021 | OTLK | $17.9K | Sale | 8,554 | $2.09 | Discretionary |
| Feb 12, 2021 | OTLK | $145.3K | Sale | 56,973 | $2.55 | Discretionary |
| Mar 19, 2020 | OTLK | $0 | Award | 1,207,457 | $N/A | Discretionary |